{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:32:10Z","timestamp":1790526730186,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/leu.2016.34","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T07:40:23Z","timestamp":1456126823000},"page":"1263-1272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["TGF-\u03b1 and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy"],"prefix":"10.1038","volume":"30","author":[{"given":"E","family":"Nievergall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C H","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D B","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Biondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S J","family":"Busfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Vairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W N","family":"Erber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sadras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Grose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D T","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A F","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D K","family":"Hiwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"key":"BFleu201634_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u20131061.","journal-title":"Leukemia"},{"key":"BFleu201634_CR2","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu201634_CR3","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu201634_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232\u2013238.","journal-title":"J Clin Oncol"},{"key":"BFleu201634_CR5","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096\u20132102.","journal-title":"Leukemia"},{"key":"BFleu201634_CR6","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013; 121: 3818\u20133824.","journal-title":"Blood"},{"key":"BFleu201634_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","volume":"125","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A et al. TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015; 125: 915\u2013923.","journal-title":"Blood"},{"key":"BFleu201634_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123: 1353\u20131360.","journal-title":"Blood"},{"key":"BFleu201634_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","volume":"120","author":"D Marin","year":"2012","unstructured":"Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 2012; 120: 291\u2013294.","journal-title":"Blood"},{"key":"BFleu201634_CR10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A . Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356\u20131363.","journal-title":"J Clin Oncol"},{"key":"BFleu201634_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/leu.2011.251","volume":"26","author":"A Pardanani","year":"2012","unstructured":"Pardanani A, Finke C, Lasho TL, Al-Kali A, Begna KH, Hanson CA et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia 2012; 26: 693\u2013699.","journal-title":"Leukemia"},{"key":"BFleu201634_CR12","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1182\/blood-2010-01-262071","volume":"116","author":"SM Kornblau","year":"2010","unstructured":"Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR . Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010; 116: 4251\u20134261.","journal-title":"Blood"},{"key":"BFleu201634_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011; 20: 661\u2013673.","journal-title":"Cancer Cell"},{"key":"BFleu201634_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang B, Ho Yin W, Huang Q, Maeda T, Lin A, Lee S-u et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 2012; 21: 577\u2013592.","journal-title":"Cancer Cell"},{"key":"BFleu201634_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.molonc.2008.07.003","volume":"2","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Gstoettenbauer A, Colinge J, Kaupe I, Bilban M, Burkard TR et al. The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol Oncol 2008; 2: 272\u2013281.","journal-title":"Mol Oncol"},{"key":"BFleu201634_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson WE, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118\u2013127.","journal-title":"Biostatistics"},{"key":"BFleu201634_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L . Random forests. Mach Learn 2001; 45: 5\u201332.","journal-title":"Mach Learn"},{"key":"BFleu201634_CR18","first-page":"18","volume":"2","author":"A Liaw","year":"2002","unstructured":"Liaw A, Wiener M . Classification and regression by randomForest. R News 2002; 2: 18\u201322.","journal-title":"R News"},{"key":"BFleu201634_CR19","volume-title":"Classification and Regression Trees","author":"L Breiman","year":"1984","unstructured":"Breiman L, Friedman J, Olshen R, Stone C . Classification and Regression Trees. Wadsworth, 1984."},{"key":"BFleu201634_CR20","unstructured":"Therneau T, Atkinson B, Ripley B rpart: Recursive Partitioning and Regression Trees. R package version 4.1-5; 2014, Available on: http:\/\/CRAN.R-project.org\/package=rpart."},{"key":"BFleu201634_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9890-3","volume-title":"Data Mining with Rattle and R: The Art of Excavating Data for Knowledge Discovery, Use R!","author":"G Williams","year":"2011","unstructured":"Williams G . Data Mining with Rattle and R: The Art of Excavating Data for Knowledge Discovery, Use R!. Springer, 2011."},{"key":"BFleu201634_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014; 124: 511\u2013518.","journal-title":"Blood"},{"key":"BFleu201634_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","volume":"19","author":"T Schmidt","year":"2011","unstructured":"Schmidt T, Masouleh Behzad K, Loges S, Cauwenberghs S, Fraisl P, Maes C et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+ leukemia. Cancer Cell 2011; 19: 740\u2013753.","journal-title":"Cancer Cell"},{"key":"BFleu201634_CR24","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ . Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15: e493\u2013e503.","journal-title":"Lancet Oncol"},{"key":"BFleu201634_CR25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646\u2013674.","journal-title":"Cell"},{"key":"BFleu201634_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z . Inflammation and cancer. Nature 2002; 420: 860\u2013867.","journal-title":"Nature"},{"key":"BFleu201634_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature 2008; 454: 436\u2013444.","journal-title":"Nature"},{"key":"BFleu201634_CR28","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1038\/leu.2014.95","volume":"28","author":"M Braig","year":"2014","unstructured":"Braig M, Pallmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A et al. A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia 2014; 28: 2028\u20132039.","journal-title":"Leukemia"},{"key":"BFleu201634_CR29","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","volume":"122","author":"P Gallipoli","year":"2013","unstructured":"Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R et al. Autocrine TNF-\u03b1 production supports CML stem and progenitor cell survival and enhances their proliferation. Blood 2013; 122: 3335\u20133339.","journal-title":"Blood"},{"key":"BFleu201634_CR30","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood.V99.6.2265","volume":"99","author":"S Verstovsek","year":"2002","unstructured":"Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002; 99: 2265\u20132267.","journal-title":"Blood"},{"key":"BFleu201634_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/sj.leu.2402769","volume":"17","author":"P Korkolopoulou","year":"2003","unstructured":"Korkolopoulou P, Viniou N, Kavantzas N, Patsouris E, Thymara I, Pavlopoulos PM et al. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 2003; 17: 89\u201397.","journal-title":"Leukemia"},{"key":"BFleu201634_CR32","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","volume":"96","author":"A Aguayo","year":"2000","unstructured":"Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240\u20132245.","journal-title":"Blood"},{"key":"BFleu201634_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/leu.2008.255","volume":"23","author":"HF Negaard","year":"2009","unstructured":"Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009; 23: 162\u2013169.","journal-title":"Leukemia"},{"key":"BFleu201634_CR34","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/sj.leu.2402486","volume":"16","author":"A Janowska-Wieczorek","year":"2002","unstructured":"Janowska-Wieczorek A, Majka M, Marquez-Curtis L, Wertheim JA, Turner AR, Ratajczak MZ . Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 2002; 16: 1160\u20131166.","journal-title":"Leukemia"},{"key":"BFleu201634_CR35","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1084\/jem.20060844","volume":"203","author":"C Chiodoni","year":"2006","unstructured":"Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C et al. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 2006; 203: 2441\u20132450.","journal-title":"J Exp Med"},{"key":"BFleu201634_CR36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","volume":"29","author":"MY Konopleva","year":"2011","unstructured":"Konopleva MY, Jordan CT . Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011; 29: 591\u2013599.","journal-title":"J Clin Oncol"},{"key":"BFleu201634_CR37","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","volume":"121","author":"B Zhang","year":"2013","unstructured":"Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-Cadherin and Wnt-\u03b2-catenin signaling. Blood 2013; 121: 1824\u20131838.","journal-title":"Blood"},{"key":"BFleu201634_CR38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature08734","volume":"463","author":"K Naka","year":"2010","unstructured":"Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676\u2013680.","journal-title":"Nature"},{"key":"BFleu201634_CR39","doi-asserted-by":"publisher","first-page":"e23022","DOI":"10.1371\/journal.pone.0023022","volume":"6","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V et al. Chronic myeloid leukemia patients in prolonged remission following Interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011; 6: e23022.","journal-title":"PLoS One"},{"key":"BFleu201634_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.it.2014.12.008","volume":"36","author":"J Mauer","year":"2015","unstructured":"Mauer J, Denson JL, Bruning JC . Versatile functions for IL-6 in metabolism and cancer. Trends Immunol 2015; 36: 92\u2013101.","journal-title":"Trends Immunol"},{"key":"BFleu201634_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","volume":"130","author":"KE Panteli","year":"2005","unstructured":"Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005; 130: 709\u2013715.","journal-title":"Br J Haematol"},{"key":"BFleu201634_CR42","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood.V85.12.3636.bloodjournal85123636","volume":"85","author":"R Bhatia","year":"1995","unstructured":"Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM . Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995; 85: 3636\u20133645.","journal-title":"Blood"},{"key":"BFleu201634_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/leu.2014.260","volume":"29","author":"TR Rosean","year":"2014","unstructured":"Rosean TR, Tompkins VS, Olivier AK, Sompallae R, Norian LA, Morse HC 3rd et al. The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. Leukemia 2014; 29: 233\u2013237.","journal-title":"Leukemia"},{"key":"BFleu201634_CR44","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/onc.2012.458","volume":"32","author":"WH Huang","year":"2013","unstructured":"Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL, Hung SC . Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 2013; 32: 4343\u20134354.","journal-title":"Oncogene"},{"key":"BFleu201634_CR45","doi-asserted-by":"publisher","first-page":"9176","DOI":"10.1158\/0008-5472.CAN-05-1556","volume":"65","author":"N Ishikawa","year":"2005","unstructured":"Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005; 65: 9176\u20139184.","journal-title":"Cancer Res"},{"key":"BFleu201634_CR46","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1111\/j.1349-7006.2008.00931.x","volume":"99","author":"K Masago","year":"2008","unstructured":"Masago K, Fujita S, Hatachi Y, Fukuhara A, Sakuma K, Ichikawa M et al. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci 2008; 99: 2295\u20132301.","journal-title":"Cancer Sci"},{"key":"BFleu201634_CR47","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1200\/JCO.2010.31.0805","volume":"28","author":"CL Addison","year":"2010","unstructured":"Addison CL, Ding K, Zhao H, Le Maitre A, Goss GD, Seymour L et al. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 2010; 28: 5247\u20135256.","journal-title":"J Clin Oncol"},{"key":"BFleu201634_CR48","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","volume":"119","author":"H Zhang","year":"2012","unstructured":"Zhang H, Li H, Xi HS, Li S . HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells. Blood 2012; 119: 2595\u20132607.","journal-title":"Blood"},{"key":"BFleu201634_CR49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2005.06.038","volume":"186","author":"AC Dreux","year":"2006","unstructured":"Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA . The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis 2006; 186: 38\u201353.","journal-title":"Atherosclerosis"},{"key":"BFleu201634_CR50","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/ncb3031","volume":"16","author":"H Lanaya","year":"2014","unstructured":"Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol 2014; 16: 972\u2013981.","journal-title":"Nat Cell Biol"},{"key":"BFleu201634_CR51","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1210\/jcem-68-2-486","volume":"68","author":"K Pesonen","year":"1989","unstructured":"Pesonen K, Viinikka L, Myllyla G, Kiuru J, Perheentupa J . Characterization of material with epidermal growth factor immunoreactivity in human serum and platelets. J Clin Endocrinol Metab 1989; 68: 486\u2013491.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFleu201634_CR52","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1677\/joe.0.1180501","volume":"118","author":"S MacNeil","year":"1988","unstructured":"MacNeil S, Dawson RA, Crocker G, Barton CH, Hanford L, Metcalfe R et al. Extracellular calmodulin and its association with epidermal growth factor in normal human body fluids. J Endocrinol 1988; 118: 501\u2013509.","journal-title":"J Endocrinol"},{"key":"BFleu201634_CR53","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1126\/science.2422759","volume":"232","author":"AB Schreiber","year":"1986","unstructured":"Schreiber AB, Winkler ME, Derynck R . Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250\u20131253.","journal-title":"Science"},{"key":"BFleu201634_CR54","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1091\/mbc.2.8.599","volume":"2","author":"R Ebner","year":"1991","unstructured":"Ebner R, Derynck R . Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell regulation 1991; 2: 599\u2013612.","journal-title":"Cell regulation"},{"key":"BFleu201634_CR55","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1600-0854.2009.00943.x","volume":"10","author":"K Roepstorff","year":"2009","unstructured":"Roepstorff K, Grandal MV, Henriksen L, Knudsen SL, Lerdrup M, Grovdal L et al. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 2009; 10: 1115\u20131127.","journal-title":"Traffic"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201634","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:19:33Z","timestamp":1648743573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFleu201634"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.34","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,22]]},"assertion":[{"value":"14 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JR is a Novartis Shareholder. DTY and TPH receive honoraria and research funding from Novartis Oncology, Bristol-Myers Squibb and Ariad. DLW receives research funding from Novartis Oncology, Bristol-Myers Squibb and Ariad. MB and GV are employed by CSL Limited, and SJB was employed by CSL Limited. EN, CHK, DBW, KF, WNE, TS, RG, AFL and DKH declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}